INTRODUCTION
involved in homeostatic trafficking such as SDF-1, BCA-1 and SLC are constitutively expressed, while inflammatory chemokines are induced under specific pathological conditions. The inflammatory chemokines, monocyte chemoattractant protein 1 (MCP-1/CCL2) and macrophages-inflammatory protein 1a (MIP-1a/CCL3), both members of the CC-subfamily, are potent chemotactic agents for monocytes, but induce migration also of other peripheral blood cells. 4 In vivo studies have shown MCP-1 and MIP-1a to be the major chemoattractants in host defense and inflammation. 5, 6 Both MCP-1 and MIP-1a are produced by a variety of cells such as endothelial cells, vascular smooth muscle cells, fibroblast and monocytes in response to different stimuli such as proinflammatory cytokines (TNF-a, IL-1, IL-6, IFN-g), lipopolysaccharide (LPS) from Gram-negative bacteria and peptidoglycan from Gram-positive bacteria. [7] [8] [9] The anti-inflammatory cytokines IL-4, IL-10 and IL-13 have been shown to suppress LPS-induced chemokine production in peripheral human blood monocytes. [10] [11] [12] MCP-1 is the most extensively studied CC-chemokine and induces migration of monocytes under many different pathological conditions including arteriosclerosis, 1, 13, 14 rheumatoid arthritis, 15 pulmonary fibrosis and granulomatous disease. 16 MIP-1a appears to be important also in antiviral immunity 6 and several studies have shown that MIP-1a together with RANTES and MIP-1b are able to suppress human immunodefiency virus (HIV) infection. 17, 18 At least two subtypes of MIP-1a have been identified, LD78a and the non-allelic variant LD7b. The latter has been shown to be the most potent chemokine inhibitor of HIV entry. 19 MCP-1 mediates its effects through the seven-transmembrane G-protein-coupled receptor CCR2. CCR2B is present in two isoforms A and B, differing only in their alternatively spliced carboxy tail, 20 where the CCR2B isoform is the dominant form in monocytes. 21 CCR2 is expressed on other cells such as activated T-lymphocytes, 22 B-cells 23 and NK-cells. 24 Binding of MCP-1 to CCR2 leads to an increase in cytosolic free calcium, integrin activation and monocyte migration. 25, 26 The importance of this receptor is shown in CCR2 knockout mice (CCR2 -/-) who have impaired recruitment of macrophages to sites of inflammation. 27 The expression of CCR2 on monocytes is down-regulated by various pro-inflammatory cytokines (TNF-a, IL-6, IL-1, IFN-g), growth factors (GM-CSF, M-CSF), MCP-1 itself, [28] [29] [30] [31] [32] LPS from Escherichia coli, oxidized LDL and during differentiation of monocytes to macrophages. [33] [34] [35] [36] The anti-inflammatory cytokine IL-10 has been shown to inhibit the down-regulation of CCR2 induced by LPS and IFN-g. 37 Various bacterial cell wall components, also often referred to as pathogen-associated molecular pattern (PAMP), may be responsible for the immunostimulatory activities during acute inflammatory processes. These cell wall components exert their actions mainly through interacting with monocytes and macrophages. By ligating the pattern recognition receptors CD14 and Toll-like receptors (TLRs), PAMPs frequently lead to activation of NF-kB and to the expression of early immediate genes. [38] [39] [40] [41] We have previously shown that two PAMPs, LPS from E. coli and non-capped lipoarabinomannan (AraLAM) from Mycobacteria sp., both activate NF-kB and induce expression of the early immediate genes TNF-a and tissue factor in purified human blood monocytes. 42 In the present investigation, we extend our studies on the effects of PAMPs to include LPS from the Gram-negative bacteria Neisseria meningitidis and LTA from the Gram-positive bacteria Staphylococcus aureus in addition to two different LPS from E. coli and AraLAM from Mycobacteria sp. We hypothesize that these PAMPs, depending on their substructures, will induce varying production of MCP-1 and MIP-1a in cryopreserved highly purified human blood monocytes and that these PAMPs all will have an effect on the expression of CCR2 on monocytes. Finally, we ask to what extent the anti-inflammatory cytokines IL-4, IL-10 and IL-13 and antibodies against CD14, TLR2 and TLR4 suppress the effects of these PAMPs.
MATERIALS AND METHODS

Reagents and solutions
Cell culture medium consisted of RPMI 1640 with 25 mM HEPES buffer and L-glutamine (Gibco Life Technologies Ltd, Paisley, UK) supplemented with 10 or 20% v/v acidand heat-treated fetal calf serum (AT-FCS) (Bio Whittaker Inc., Walkersville, MD, USA) and penicillin (100 U/ml)/streptomycin (0.1 mg/ml) (AT-FCS/RPMI 1640-P/S). Three different lipopolysaccharides (LPS) from Gram-negative bacteria were used: (i) LPS from E. coli O55:B5 (E. coli-LPS) (BioWhittaker Inc.); (ii) highly purified LPS from E. coli O111:B4 (Pur-LPS) re-extracted as described by Hirschfeld et al. 43 (kindly provided by Dr Stefanie N. Vogel, University of Maryland, Baltimore, MD, USA); and (iii) LPS from Neisseria meningitidis strain 44/76 (Nm-LPS) purified as described by Brandtzaeg et al. 44 All LPS preparations were reconstituted with endotoxin-free water (1 mg/ml), stored at -70°C and further diluted with 10% v/v AT-FCS/RPMI 1640-P/S to the required concentrations. Freeze-dried, butanol extracted, lipoteichoic acid (LTA) from the Gram-positive bacteria S. aureus (kindly provided by Dr Thomas Hartung, University of Konstanz, Konstanz, Germany) 45, 46 and lipoarabinomannan (AraLAM) from non-mannose-capped, rapid growing Mycobacterium sp. (kindly provided by Dr John T. Belisle, Colorado State University, Fort Collins, CO, USA) were both reconstituted with endotoxin-free water (1 mg/ml and 200 mg/ml, respectively) and further diluted as above.
Fluo-3 AM (Molecular Probes, Eugene, OR, USA) was dissolved in dimethyl sulfoxide (Merck, Darmstadt, Germany) (stock solution 440 mM). Normal physiological buffer (NPB) was composed of (in mM): 120.0 NaCl, 3.3 KCl, 1.2 KH 2 PO 4 , NaHCO 3 , 1.0 CaCl 2 , 0.8 MgSO 4 and 0.1% w/v BSA (Sigma-Aldrich, St Louis, MO, USA). Propidium iodide (PI) (Sigma-Aldrich) was dissolved and diluted with PBS (0.1 mg/ml) and stored at -20°C.
Cytokines and antibodies
Recombinant human MCP-1 (rMCP-1), cytokines rIL-4, rIL-10 and rIL-13, and monoclonal anti-human antibodies (mAb) against IL-4, IL-10 and IL-13 were all purchased from R&D Systems Inc. (Minneapolis, MN, USA). Anti-CD14 mAb: clone 60bca (ATCC, Rockville, MD, USA), purified and provided by Dr David Warren (The Norwegian Radiumhospital, Oslo, Norway), and clone 18D11 (Diatec.com AS, Oslo, Norway). Anti-TLR2 mAb (clone TLR2.1) and anti-TLR4 mAb (clone HTA125) were kindly provided by Dr Terje Espevik (Institute of Cancer and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway). As isotype control, mAbs IgG 1 and IgG 2a without azide were used (Diatec.com AS). FITC-conjugated CD14 (MY4-FITC) and isotype IgG 2b mAbs were from Beckman Coulter (Miami, FL, USA). For detection of CCR2, biotin-conjugated mAb was purchased from R&D Systems (clone 48607.211) and FITC-conjugated avidin D from Vector Laboratories (Burlingame, CA, USA). As isotype control, a biotin-conjugated IgG 2b mAb from R&D Systems was used (clone 20116.11).
Isolation of human peripheral blood monocytes
Human peripheral blood monocytes were isolated from healthy donors as previously described. 47 Briefly, PBMCs were isolated by density gradient centrifugation on Lymphoprep™(d = 1.077 g/ml: AXIS-SHIELD PoC AS, Oslo, Norway) and further purification of monocytes from PBMCs was done using centrifugal elutriation (Beckman JE-6B centrifuge, Palo Alto, CA, USA). 48, 49 Flow cytometry (FACSort, Becton Dickinson, San Jose, CA, USA) and the FITC-conjugated CD14 mAb (MY4-FITC) was used to determine monocyte purity (> 95%). Subsequent to elutriation purification, the monocytes from each donor were subjected to cryopreservation using DMSO and stored at -150°C (1 ml, 6 x 10 6 cells/ml). 47 Prior to culturing, the cells from a single donor were thawed (37°C), diluted in 20% v/v AT-FCS/RPMI 1640 (9 ml), centrifuged (201 g, 20°C, 10 min), the supernatant discarded and the cells resuspended and diluted with 10% v/v AT-FCS/RPMI 1640-P/S to appropriate concentrations. Cells from different donors were used when repeating an experiment.
Stimulation and culture conditions of purified human blood monocytes
Purified human blood monocytes from a single donor were seeded (100 ml, 1.0 x 10 6 cells/ml) in 96-well cell culture plates (Costar ® , Corning Inc., Acton, MA, USA) in the absence or presence of the bacterial cell wall components (PAMPs) (50 ml) E. coli-LPS, Pur-LPS, Nm-LPS, LTA or AraLAM, incubated (37°C, 5% v/v CO 2 ) for varying time intervals (0, 3, 6, 12 and 24 h) in a total volume of 200 ml. After incubation, the plates were centrifuged (100 g, 4°C, 10 min), supernatants collected, stored at -70°C and analysed for MCP-1 and MIP-1a within 14 days. Optimal final concentrations of E. coli-LPS, LTA and AraLAM were determined in pilot experiments. The optimal concentration of E. coli-LPS was found to be 0.1 ng/ml and used for all three LPS preparations in further experiments whereas 10 mg/ml of LTA and AraLAM were used, if not otherwise described.
The effects of rIL-4, rIL-10 and rIL-13 on MCP-1 and MIP-1a production were studied by adding increasing concentrations of these cytokines (final concentration 0.001-100 ng/ml, 25 ml) to the monocytes prior to (15 min, 20°C) incubation with the PAMPs (37°C, 5% v/v CO 2 ). The cytokine effects were blocked by adding mAbs (25 ml) against IL-4 and IL-10 (final concentration 10 mg/ml) and IL-13 (final concentration 20 mg/ml) to the cell cultures in addition to the cytokines and prior to (15 min, 20°C) E. coli-LPS. The effects of mAbs against CD14 (60bca and 18D11), TLR2 (TLR2.1) and TLR4 (HTA125) on the MCP-1 and MIP-1a production were studied by adding these antibodies (final concentration 10 mg/ml) prior to (15 min, 20°C) incubation with the PAMPs (37°C, 5% v/v CO 2 ) (final concentrations E. coli-LPS and Pur-LPS 0.1 ng/ml, Nm-LPS 0.01 ng/ml, LTA 0.1 mg/ml, AraLAM 1 mg/ml). All supernatants were collected after 24 h, stored at -70°C and analysed within 14 days.
Chemokine quantification
MCP-1 and MIP-1a antigens in the cell culture supernatants were quantified by ELISA according to the manufacturer's instructions (R&D Systems and Biosource International, Camarillo, CA, USA). Detection limits were 5 and 2 pg/ml, respectively.
Isolation and quantification of MCP-1-and MIP-1a-(LD78a and LD78b) mRNA
Monocytes (100 ml, 1 x 10 6 cells/ml) were seeded and cultured in the absence or presence of PAMPs as above for 0, 1, 3, 6, 12 and 24 h (37°C, 5% v/v CO 2 ). Supernatants were discarded and cell lysates made by addition of 150 ml lysis & binding solution (1 min, 4°C) (MagAttract™ Direct mRNA kit, Qiagen Inc., Valencia, CA, USA) and stored at -70°C. Subsequently, the lysates (125 ml) were subjected to robotized mRNA isolation (GenoM48, Qiagen Inc.) using oligo-d(T)beads (MagAttract™ Direct mRNA kit). Reverse transcription of mRNA to cDNA and subsequently PCR was performed essentially according to Øvstebø et al. 50 Quantification of cDNAs was performed using real-time PCR (LightCycler™, Roche Diagnostics GmbH, Mannheim, Germany), SYBR Green fluorescence detection and PCR-based standard curves prepared as previously described. 50 Optimized, specific PCR primers designed in Primer3 (<www-genome.wi.mit.edu/genome_software/ other/primer3.html>) were used. Primer sequences were:
-actin (203 bp PCR-product) 5¢-GGC-ATC-CTC-ACC-CTG-AAG-TA-3¢ and 5¢-GGG-GTG-TTG-AAG-GTC-TCA-AA-3¢ , b 2 -microglobulin (165 bp PCR-product) 5¢-TAT-CCA-GCG-TAC-TCC-AAA-GA-3¢ and 5¢-GAC-AAG-TCT-GAA-TGC-TCC-AC-3¢ (Eurogentec s.a., Seraing, Belgium). The PCR products were sequenced (Beckman Coulter CEQ-2000, Miami, FL, USA) (DNA Sequencing Core Facility, Medical Faculty, University of Oslo, Norway) and homology with MCP-1, MIP-1a (LD78a and LD78b), b-actin and b 2 -microglobulin sequences examined using the NCBI gene Blast™ website (<www.ncbi.nlm.nih.gov/ blast>). mRNA and cDNA controls were used to evaluate the RT-PCR system. 50 To exclude genomic DNA lysates were subjected to RT-PCR using MCP-1 primers but without Omniscript Reverse Transcriptase (DCrossing point [Cp] of genomic-target was regularly more than 10 Cp). The PCR-efficiencies were determined for the different targets (MCP-1, MIP-1a (LD78a and LD78b), b-actin and b 2 -microglobulin). Similar efficiencies (1.89) were obtained for MCP-1 and MIP-1a (LD78a) allowing the use of the same standard curve for conversion of the Cp to concentrations. 51 b-Actin and to some extent b 2 -microglobulin were used as internal controls to normalize each sample for variations in mRNA isolation and RT-PCR-efficiency. Because of differences in efficiencies between MCP-1 and MIP-1a (LD78a) as compared to b-actin (1.96), the concentrations of MCP-1 and MIP-1a (LD78a) were efficiency corrected as previously described. 50 All target concentrations were expressed as ratios between chemokine and the internal control.
Flow cytometry
Monocytes (500 ml, 1.5 x 10 6 cells/ml) were seeded in 24-well cell culture plates (Costar ® , Corning Inc.) in the absence or presence of (250 ml) E. coli-LPS, Pur-LPS, Nm-LPS (final concentration 1 ng/ml), LTA or AraLAM (final concentration 10 mg/ml) and incubated (37°C, 5% v/v CO 2 ) for varying time intervals (0, 3, 6 or 24 h). In some experiments, rIL-4, rIL-10 or rIL-13 (final concentration 10 ng/ml, 250 ml) was added prior to (30 min,
For detection of CCR2, the monocytes (1.0 x 10 5 ) were washed (4 ml CellWASH: Becton Dickinson) and incubated (30 min, 4°C) with 20 ml biotin-conjugated CCR2 antibody or 20 ml biotin-conjugated IgG 2b mAb for the isotype control. Subsequently, the monocytes were washed (4 ml 0.5% w/v BSA CellWASH), centrifuged (300 g, 4°C, 7 min) and resuspended in 50 ml 0.5% w/v BSA CellWASH. FITC-conjugated avidin D (10 ml, diluted 1:100 with 0.5% w/v BSA CellWASH) was added, the monocytes incubated (30 min, 4°C), washed once (4 ml 0.5% w/v BSA CellWASH) and resuspended in 350 ml 0.5% w/v BSA CellWASH before analysing. The samples were analysed using a FACSort™ flow cytometer and the data acquired and analysed with CellQuest software (Becton Dickinson). Data from 10,000 CD14 positive events were collected from each sample with light scatter gain in the linear mode and the fluorescence gain in the logarithmic mode. Cell viability was analysed using propidium iodide (PI) (15 s, 20°C) (final concentration 1.5 mg/ml) and the expression of CCR2 was studied on PI-negative monocytes. Median fluorescence intensities (MFI) were converted to Molecules of Equivalent Soluble Fluorochromes (MESF) using microbeads (Quantum™26, Bangs laboratories Inc., IN, USA). Specific fluorescence was obtained by subtracting the MESF obtained from the isotype control from the MESF obtained from the CCR2 labeled sample.
For cytosolic free calcium ([Ca 2+ ] i ) measurements, the Ca 2+ sensitive Fluo-3 AM probe, which is cell membrane permeable, was used. Unstimulated monocytes (1 x 10 5 ) or monocytes stimulated with PAMPs (final concentration as above) were incubated (37°C, 5% v/v CO 2 ) in NPB containing Fluo-3 AM (final concentration 2.2 mM) for 20 min, washed twice with NPB, and rMCP-1 (final concentration 50 ng/ml) was added prior to (20 s, 20°C) analysing by flow cytometry. Data from 10,000 events were collected from each sample with light scatter gain in the linear mode and the fluorescence gain set in the logarithmic mode. Results are given as arbitrary units (a.u.), calculated by dividing the Fluo-3 median fluorescence intensity (MFI) obtained from rMCP-1 stimulated monocytes (10,000 events as above) by the MFI from cells without addition of rMCP-1. Only MFI from PI-negative cells were registered.
MCP-1 binding and consumption
Monocytes (100 ml, 2.0 x 10 6 cells/ml) were seeded and cultured in the absence or presence of E. coli-LPS (final concentration 0.1 ng/ml) and incubated (37°C, 5% CO 2 ) for 3 h. Subsequently, supernatants were discarded and monocytes incubated (37°C, 5% v/v CO 2 ) in the absence or presence of exogenous rMCP-1 (final concentration 1 ng/ml, 100 ml) for varying time intervals (0, 30, 60, 90 and 120 min), the supernatants collected, stored at -70°C and analysed within 14 days for MCP-1. To calculate the amount of MCP-1 bound and consumed from the medium during the 120 min time-course, the concentration of endogenously produced MCP-1 by unstimulated and E. coli-LPS stimulated monocytes was quantified in separate wells and subtracted from the MCP-1 concentration in the supernatants obtained from wells boosted with exogenous rMCP-1.
Detection of endotoxin levels
All reagents and solutions were analysed for the presence of LPS using the Limulus amebocyte lysate (LAL) assay as previously described. 52 All reagents and solutions contained less than 25 pg/ml of endotoxin (0.25 EU/ml). The endotoxin levels in the final dilutions of the LTA and AraLAM were less than 25 pg/ml.
RESULTS
Production of MCP-1 and MIP-1a (protein and mRNA) by purified human blood monocytes stimulated with bacterial cell wall components (PAMPs)
Monocytes expressed high protein levels of both MCP-1 and MIP-1a after stimulation with the different PAMPs. MCP-1 production increased more slowly than MIP-1a production during the first 6 h of incubation. During the 12-24 h time frame, however, MCP-1 production increased significantly and attained very high levels (Fig. 1A,B ). Generally, all the PAMPs, except Nm-LPS, induced a higher MCP-1 production compared to MIP-1a production after 24 h of stimulation. Due to large donor variations the results are given as fold increase ± SEM compared to concentrations at 0 h. The production of MCP-1 increased from 455 ± 50 times (Nm-LPSstimulated monocytes) to 2182 ± 450 times (AraLAMstimulated monocytes) at 24 h (Fig. 1A) . Nm-LPS induced significantly lower MCP-1 production (P < 0.05) compared to the other PAMPs (Fig. 1A) . The production of MIP-1a increased from 277 ± 109 times (AraLAM-stimulated monocytes) to 681 ± 201 times (Nm-LPS-stimulated monocytes) at 24 h but there were no significant differences between the various PAMPs' responses ( Fig. 1B) .
Based on chemokine/b-actin mRNA ratios, high levels of mRNA for both MCP-1 and MIP-1a (LD78a) were induced by all PAMPs (Fig. 2A,B) while MIP-1a (LD78b) mRNA could not be detected. The results are from a representative experiment (n = 3). Similar results were shown using b 2 -microglobulin instead of b-actin (results not shown). As observed for protein production, MCP-1 mRNA ratios showed an initial slower increase than the MIP-1a (LD78b) mRNA ratios. After 24 h, the MCP-1 mRNA ratios were higher than the MIP-1a (LD78b) mRNA ratios. The highest ratios of MCP-1 mRNA were obtained after 24 h of incubation and ranged from 4.7 (Nm-LPS-stimulated monocytes) to 12.0 (AraLAM-stimulated monocytes). In contrast, the MIP-1a mRNA ratios peaked after 6 h and ranged from 2.8 (LTA-stimulated monocytes) to 16.8 (Nm-LPS-stimulated monocytes) where Nm-LPS induced higher mRNA ratio compared to the other PAMPs (Fig. 2B) . PAMP, pathogen-associated molecular pattern; ND, 50% inhibition could not be determined.
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Inhibitory effects of rIL-4, rIL-10 and rIL-13 on the production of MCP-1 and MIP-1a by purified human blood monocytes stimulated with PAMPs
It has previously been shown that the anti-inflammatory cytokines IL-4, IL-10 and IL-13 all have an inhibitory effect on the production of IL-8 and MCP-1 by LPSstimulated monocytes. 10 Therefore, we examined the effects of rIL-4, rIL-10 and rIL-13 on the production of MCP-1 and MIP-1a by monocytes stimulated with the five different PAMPs by determining the IC 50 (50% inhibition of the chemokine production) of rIL-4, rIL-10 and rIL-13 ( Table 1 ). The IC 50 values of rIL-4 for both the MCP-1 and the MIP-1a production were lower than those of rIL-10 and rIL-13 for all PAMPs. As for rIL-10, a 50% inhibition could not be determined in monocytes stimulated with Nm-LPS and LTA. Generally, the IC 50 values were lower for all three cytokines for the production of MIP-1a as compared with the production of MCP-1. However, LTA-stimulated monocytes demonstrated a higher IC 50 of rIL-13 for MIP-1a as compared with MCP-1 production. Addition of mAbs against the various cytokines examined reversed the anti-inflammatory effects of the E. coli-LPS induced chemokine production, demonstrating the inhibitory effects to be due to these cytokines (Fig. 3) .
Effects of mAbs against CD14, TLR2 and TLR4 on the production of MCP-1 and MIP-1a by purified human blood monocytes stimulated with PAMPs
Previous studies have shown that LPSs from several Gram-negative bacteria mediate their cellular activities through CD14 and TLR4 while LTA and AraLAM operate through CD14 and TLR2. [38] [39] [40] 53 Therefore, we studied the effects of antibodies against these receptors on the production of MCP-1 and MIP-1a by monocytes stimulated with PAMPs. The anti-CD14 mAb 60bca inhibited the production of both chemokines induced by E. coli-LPS, Pur-LPS and Nm-LPS completely (Fig. 4) . MCP-1 production induced by LTA and AraLAM was significantly inhibited by anti-CD14 mAb 60bca by 86 ± 4% and 94 ± 2% (P < 0.05), respectively, whereas MIP-1a production, induced by LTA and AraLAM, was significantly inhibited by 82 ± 6% and 92 ± 1% (P < 0.05), respectively, (Fig. 4) . By using the anti-CD14 mAb 18D11, similar results were observed (data not shown). LTA-induced MCP-1 and MIP-1a production was inhibited significantly by anti-TLR2 mAb TLR2.1 by 53 ± 3% and 42 ± 6% (P < 0.05), respectively, while AraLAM-induced chemokine production was inhibited significantly by 45 ± 10% and 36 ± 7% (P < 0.05), respectively. Anti-TLR4 mAb HTA125 inhibited significantly the production of both chemokines
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Expression of CCR2 on purified human blood monocytes stimulated with PAMPs
Several studies have shown that LPS down-regulates the expression of CCR2 on human peripheral monocytes. 33 Therefore, we examined the effects of the five PAMPs on CCR2 expression on monocytes. CCR2 expression on unstimulated monocytes increased to 137 ± 19% during the first 6 h of incubation and decreased to 89 ± 5% at 24 h (Fig. 5 ). All five PAMPs caused a significant (P < 0.05) down-regulation of CCR2 expression after 3, 6 and 24 h compared to unstimulated cells, but no significant differences were observed between the various PAMPs tested.
In PAMPs-stimulated cells, CCR2 expression was reduced to 80% after 3 h, to 40% after 6 h, and to 15-28% after 24 h (Fig. 5 ). We further examined the effects of rIL-4, rIL-10 and rIL-13 on the expression of CCR2 on unstimulated or E. coli-LPS stimulated monocytes. CCR2 expression was not affected by these cytokines neither on unstimulated nor on E. coli-LPS stimulated monocytes (data not shown).
Effects of PAMPs on cytosolic free calcium ([Ca 2+ ] i ) in purified human blood monocytes
Chemokine binding to its receptor leads to an increase in [Ca 2+ ] i . 54, 55 Thus, we examined the ability of rMCP-1 to induce an increase in [Ca 2+ ] i in monocytes stimulated with the five different PAMPs. The results are from a representative experiment (n = 3). Addition of rMCP-1 to Fluo-3 AM loaded unstimulated monocytes led to an increase in [Ca 2+ ] i from 4.5 arbitrary units (a.u.) at 0 h to 4.7 a.u. after 6h (Fig. 6) 
Binding and consumption of rMCP-1 by unstimulated and E. coli-LPS stimulated purified human blood monocytes
To study and compare the ability of unstimulated monocytes and E. coli-LPS stimulated monocytes to bind and consume MCP-1, exogenous rMCP-1 was added to the monocytes and the residual exogenous rMCP-1 measured in the medium as a function of time. Binding increased with time both in unstimulated and in E. coli-LPS stimulated monocytes (Fig.  7) . No significant differences were observed between the MCP-1 binding by unstimulated and E. coli-LPS stimulated monocytes after 30 or 60 min ( Fig. 7 ). Significant differences occured after 90 and 120 min of incubation where, respectively, 30 ± 2.2% and 39 ± 0.7% of the exogenously added 
DISCUSSION
In the present study, we show that PAMPs from both Gram-negative (LPS) and Gram-positive bacteria (LTA) and from Mycobacteria sp. (AraLAM) induce highly purified blood monocytes to produce the CCchemokines MCP-1 and MIP-1a and to down-regulate the chemokine receptor CCR2. The PAMPs used in this study were carefully chosen. Highly purified E. coli-LPS (Pur-LPS) was used since several investigators have shown that commercial LPS might contain protein contaminants known to be bioactive. 43 We have also included LPS from N. meningitidis (Nm-LPS) since this type of LPS is structurally different from E. coli-LPS. LPS-free bioactive lipoteichoic acid (LTA) from S. aureus obtained by gentle purification using butanol 46 was used instead of commercially purified LTA. Commercial, phenol-extracted LTA may lose its immunostimulatory effects due to partial decomposition 45 in addition to containing high concentrations of LPS, as also observed by ourselves (LAL assay). In accordance with our previous findings, 42 LTA and AraLAM had to be used at higher concentrations than LPS (10 5 -fold higher) in order to achieve similar responses as LPS. Structural composition of the PAMPs has been shown to be crucial for their co-operation with specific TLRs 56 and an explanation to the differences in stimulation potential may be due to differential recognition of structural details.
All five PAMPs led to a marked increase of MCP-1 and MIP-1a both at protein and mRNA levels compared to unstimulated monocytes (Figs 1 & 2) . Generally, the increases of MCP-1 mRNA and protein were 3-5-fold higher than the increases of MIP-1a after 24 h of stimulation. Increased response of MCP-1 as opposed to MIP-1a has also been observed by others both in in vitro 9 and in in vivo studies. 57 The induction of MIP-1a mRNA (LD78a) and protein increased more rapidly compared to MCP-1 which are in line with the findings of Wang et al. 9 MCP-1 mRNA persistently increased during the incubation time whereas the MIP-1a mRNA (LD78a) peaked after 6 h after which it declined. These mRNA data may suggest that MIP-1a (LD78a) mRNA is more unstable than the MCP-1 mRNA or that gene transcription gradually decreases. To what extent differences in MCP-1-and MIP-1a-mRNA instability caused by several AU-rich motifs 58 may add to protein production differences remain elusive. Transcription of the MCP-1 gene involves at least two different NF-kB consensus sites (A1 and A2) in the promotor region besides AP-1 and Sp1 59 , while transcription factors from the C/EBPand c-Ets-family, in addition to NF-kB, have been shown to be important for transcription of the MIP-1a gene. 60 These differences on transcriptional regulation may possibly contribute to differences in MCP-1 and MIP-1a response patterns.
Nm-LPS induced considerably less MCP-1 protein production compared to the other PAMPs, which is interesting. The structure of Nm-LPS as compared to E. coli-LPS differs in having oligosaccharides instead of polysaccharides attached to the lipid A and KDO moieties and this may possibly explain the differences in response patterns. On the other hand, Nm-LPS stimulation led to a very high expression of MIP-1a (LD78a) mRNA compared to the other PAMPs, which is not reflected at the protein level. A reason for this may be that while Nm-LPS induces a host of pro-inflammatory mediators, 61 it may also induce several proteins that affect mRNA expression and translation.
The anti-inflammatory cytokines rIL-4, rIL-10 and rIL-13 share several anti-inflammatory activities such as suppression of IL-1b, IL-6, IL-8 and TNF-a. 62, 63 Presently, we have shown that rIL-4 is a stronger inhibitor of PAMPinduced MCP-1 and MIP-1a protein production than rIL-10 and rIL-13 and that the concentrations needed to inhibit the MCP-1 production by 50% generally were higher than the concentrations needed to inhibit MIP-1a by 50% (Table  1 ). These anti-inflammatory cytokines exert their inhibitory effects through different intracellular pathways. IL-4 has Effects of PAMPs on the expression of MCP-1, MIP-1a and CCR2 by purified monocytes 357 been shown to enhance cytokine mRNA degradation 64 while IL-10 inhibits cytokine production (IL-1, IL-6, IL-8 and TNF-a) by decreasing nuclear binding of NF-kB. 64, 65 Furthermore, IL-10 inhibits MIP-1a production by reduction of mRNA half-life and by suppression of de novo synthesis of protein intermediates necessary for mRNA synthesis. 11 The inhibitory capacity of IL-13 on cytokine production has been explained as being due to preservation and induction of IkBa thus inhibiting NF-kB activation. 66 As for the strong effect of rIL-4 as opposed to rIL-10 and rIL-13 in our experiments, we suggest that the enhancing effect on mRNA degradation by rIL-4 is more efficient than the reduction of mRNA half-life by rIL-10 and inhibition of NF-kB activation by rIL-13.
In recent years, it has been known that both CD14 and TLRs are involved in mediating the inflammatory effects of different PAMPs. 38, 40, 41, 43, 53, 67 In agreement with present knowledge, we found that mAbs against CD14 and TLR4, but not TLR2, significantly inhibited both MCP-1 and MIP-1a protein production induced by E. coli-LPS, Pur-LPS and Nm-LPS (Fig. 4) . The chemokine production induced by LTA and AraLAM was inhibited by mAbs against CD14 and TLR2. Several studies have shown that LTA acts through TLR2, 40 but blocking antibodies against TLR2 have given inconsistent inhibition. 53, 68 An explanation as to why anti-TLR2 mAb TLR2.1 in some studies has been found not to inhibit the cytokine production might be due to the use of too high a concentration of LTA. 69 Regulation of CCR2 expression on monocytes is an important mechanism to control monocyte recruitment to sites of inflammation. Our results show that all five PAMPs caused a significant down-regulation of CCR2 expression during 24 h compared to unstimulated monocytes ( Fig. 5 ). Studies have demonstrated that LPS down-regulates CCR2 by reduction of mRNA half-life and by degradation and internalization of cell surface CCR2. [32] [33] [34] 70 Down-regulation of CCR2 was in our experiments accompanied by a reduced increase in [Ca 2+ ] i after stimulation with rMCP-1 (Fig. 6) . Also, the binding of significantly less exogenously added rMCP-1 indicated lower binding capacity because of reduced CCR2 expression ( Fig. 7) . Reduced binding capacity of MCP-1 to LPS-stimulated monocytes has also been demonstrated in studies using [ 125 I]-MCP-1. 33, 37, 70 In the present study, we could not demonstrate any effect of the anti-inflammatory cytokines rIL-4, rIL-10 and rIL-13 on CCR2 expression, neither on unstimulated nor E. coli-LPS stimulated monocytes (not even in the presence of IFN-g, data not shown). This is in contrast to the results published by D'Amico et al., 37 who concluded that IL-10 inhibits the down-regulation of CCR2 caused by LPS and IFN-g. To what extent differences in flow cytometry methodology and antibodies may account for these differences remains unclear.
CONCLUSIONS
MCP-1 and MIP-1a, as well as the MCP-1 receptor CCR2, will be substantially regulated upon monocyte contact with PAMPs from Gram-negative and Grampositive bacteria as well as from mycobacteria.
